CHICAGO\/BEIJING, May 11, 2025 \u2013 A novel oral medication has demonstrated remarkable success in treating a challenging form of lung cancer, according to landmark research published in The New England Journal of Medicine (NEJM) and presented at the American Association for Cancer Research (AACR) Annual Meeting.<\/p>\n
The international study, co-led by Chinese and US researchers, reveals that zongertinib \u2013 developed by Boehringer Ingelheim and Sino Biopharmaceutical \u2013 outperforms current standard treatments for HER2-mutated non-small cell lung cancer (NSCLC).<\/p>\n
Key Advantages of Zongertinib:
\n71% tumor response rate (vs. 49% with ADC therapy)
\n12.4 months progression-free survival (vs. 9.9 months)
\nDramatically reduced severe side effects (1% diarrhea cases vs. 17-26%)<\/p>\n
“This could redefine first-line treatment for HER2-mutant NSCLC,” said Prof. Wang Xin of the Chinese Academy of Medical Sciences Cancer Hospital.<\/p>\n
Global Trial with Asian Leadership<\/strong> Currently, only one FDA-approved ADC therapy exists for this cancer subtype, often causing significant side effects like fatigue, nausea, and rashes.<\/p>\n With 169 hospitals now enrolled across the US, China, and Japan, the ongoing phase 3 trial aims to confirm zongertinib\u2019s efficacy as a first-line treatment.<\/p>\n The trial highlights China\u2019s emergence as a cost-effective hub for drug development: “China delivers high-quality trials at one-tenth the cost of Western countries \u2013 that\u2019s our competitive edge,” noted **Dr. Li Jin of Shanghai\u2019s Tongji University.<\/p>\n Lung cancer remains the world\u2019s deadliest malignancy, with 2.5 million new cases and 1.8 million deaths annually. HER2 mutations affect 2-4% of NSCLC patients, representing a critical unmet need.<\/p>\n The Bottom Line:<\/strong> Source : scmp.com<\/p>\n Corporatenews24\/Us<\/p>\n","protected":false},"excerpt":{"rendered":" CHICAGO\/BEIJING, May 11, 2025 \u2013 A novel oral medication has demonstrated remarkable success in treating a challenging form of lung cancer, according to landmark research published in The New England Journal of Medicine (NEJM) and presented at the American Association for Cancer Research (AACR) Annual Meeting. Targeting HER2-Mutant NSCLC: A New Hope The international study, […]<\/p>\n","protected":false},"author":3,"featured_media":3085,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[860,857,856,859,858],"class_list":["post-3084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-china-clinical-trials","tag-her2-mutation","tag-lung-cancer-breakthrough","tag-nsclc-treatment","tag-zongertinib-trial"],"yoast_head":"\n
\nThe phase 1\/2 trial spanned 82 sites worldwide, with 188 patients (majority Asian). Key findings:
\n– Tumor shrinkage in 71% of zongertinib patients
\n– Fewer adverse events compared to intravenous antibody-drug conjugate (ADC) therapy
\n– Oral administration offers convenience over infusion-based treatments<\/p>\nPhase 3 Trials Underway<\/h3>\n
China\u2019s Growing Role in Clinical Research<\/h3>\n
\n– $41,000 per patient vs. $500,000 in the US
\n– 25 Chinese sites participating in phase 3<\/p>\nWhy This Matters<\/h3>\n
\nZongertinib could soon become the new gold standard for HER2-mutant NSCLC, offering better outcomes, fewer side effects, and greater accessibility \u2013 a win for patients and the pharmaceutical industry alike.<\/p>\n